Introduction
Unlike the earliest fluoroquinolones, several newer fluoroquinolones, including trovafloxacin, moxifloxacin, sitafloxacin and clinafloxacin, have exhibited good levels of in vitro activity against clinically important anaerobic bacteria, particularly Bacteroides species, when first introduced. [1] [2] [3] [4] [5] [6] [7] [8] For trovafloxacin, this in vitro activity was shown to correlate with in vivo efficacy which led to its licensure for the treatment of mixed aerobic-anaerobic infections. [9] [10] [11] [12] Although the use of trovafloxacin has been limited by toxicity, a number of other fluoroquinolones, including moxifloxacin and garenoxacin, are being investigated as potential treatments for anaerobic infections, including mixed intra-abdominal infections.
The introduction of the early fluoroquinolones, including ofloxacin, norfloxacin and ciprofloxacin, into clinical practice was followed by rapid emergence of fluoroquinolone resistance among some species of Enterobacteriaceae, Neisseria gonorrhoeae, Pseudomonas aeruginosa, Streptococcus pneumoniae, Staphylococcus aureus and several other pathogens. [13] [14] [15] [16] [17] [18] [19] [20] Based on the assumption that two mutations, one in the gene encoding DNA gyrase and a second in that encoding topoisomerase IV, are required to establish resistance to newer fluoroquinolones, emergence of resistance to these agents is expected to be slower. 21 We have noted increased levels of resistance for Bacteroides to trovafloxacin in recent surveys and decided to examine more fully trends in resistance since testing was first initiated until 2001. 5, 22, 23 
Materials and methods

Design
Using data from an ongoing prospective multicentre survey evaluating the susceptibility of Bacteroides spp. to a variety of antibiotics, we investigated the overall trends of Bacteroides resistance to trovafloxacin (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) , moxifloxacin, clinafloxacin and sitafloxacin (1998) (1999) (2000) (2001) , and assessed the effect of Bacteroides species, hospital and site of isolation on rates of fluoroquinolone resistance. 5, 22, 23 In addition, we compared the rates of cross-resistance between the four fluoroquinolones evaluated. We excluded isolates for which fluoroquinolone susceptibility was not carried out or data on isolation site, hospital, or species were missing. 
Medical centres
Isolate shipping and identification
Non-duplicate consecutive clinical isolates of Bacteroides species collected from all 12 centres were referred for species identification and susceptibility testing at the Anaerobe Laboratory at Tufts-New England Medical Center. Isolates were shipped on pre-reduced chopped meat agar slants (Carr Scarborough Microbiologicals, Stone Mountain, GA, USA) and were stored frozen (-70°C) until time of testing. Species identification was confirmed by means of standard methodology. 24, 25 In all tests, Bacteroides fragilis ATCC 25285 and Bacteroides thetaiotaomicron ATCC 29741 were used as controls.
Antimicrobial agents
Standard powders were provided by their respective manufacturers: clinafloxacin, Parke-Davis, Morris Plains, NJ; moxifloxacin, Bayer Corporation, West Haven, CT; sitafloxacin, Daiichi Pharmaceuticals, Montvale, NJ; trovafloxacin, Pfizer Inc., New York, NY. Antimicrobial powders were solubilized according to manufacturers' specifications.
Stock solutions of the antibiotics were prepared at 10 times the desired testing concentration and kept frozen at -70°C until the day of the test.
Susceptibility tests and MIC breakpoints
The MICs of the antibiotics were determined by agar dilution following National Committee for Clinical Laboratory Standards (NCCLS) recommendations. 26 The medium used until 1996 was brain-heart infusion agar supplemented with 5% sheep blood. After 1996, the medium was Brucella blood agar supplemented with 5 µg haemin and 1 µg vitamin K1 per mL and 5% (v/v) lysed sheep blood.
The antibiotic-containing plates were prepared in-house on the day of the test by adding two-fold serial dilutions of the corresponding antibiotic to molten agar. The bacteria were grown to logarithmic phase in brainheart infusion supplemented broth (BHIS) and their turbidity adjusted to that of a 0.5 McFarland standard (∼10 8 cfu/mL). A Steers replicator was used to deliver the inocula (10 5 cfu/spot) onto the surface of the agar plates. After the inocula had dried, the plates were inverted and incubated for 42-48 h at 37°C in an anaerobic chamber. The MIC endpoint was read at the concentration when a marked reduction occurred in the appearance of growth on the agar plate compared with that of growth on the anaerobic control plate. B. fragilis ATCC 25285 and B. thetaiotaomicron ATCC 29741 were used as controls in all the test runs. The results of susceptibility tests are presented in the tables as the geometric mean MIC, calculated as the antilog of the arithmetic average of the observed log MIC values, the MICs at which 50% and 90% of the strains were inhibited (MIC 50 and MIC 90 ), and the percentage of strains resistant at breakpoints of 1, 2, 4 and 8 mg/L. For the analysis of trovafloxacin resistance trends, the NCCLS recommended MIC breakpoint of 8 mg/L was used. For the analysis of moxifloxacin resistance trends, the NCCLS recommended MIC breakpoint for aerobes of 4 mg/L was used, since no MIC breakpoint has been determined yet.
Statistical analysis
Data were stored in a Microsoft Excel spreadsheet. Statistical analysis was carried out with the SAS system for Windows, version 8.0. Trends in geometric mean MICs over time were assessed by linear regression analysis. Trends in resistance were assessed using logistic regression for both univariate and multivariable analyses. A P value of less than 0.05 was used to determine statistical significance.
Results
A total of 4434 isolates from 12 US medical centres were analysed. Sitafloxacin was the most active fluoroquinolone, followed by clinafloxacin, trovafloxacin and moxifloxacin. Geometric mean MICs of all four fluoroquinolones have increased during the study (Table 1) with the highest increases observed for trovafloxacin and moxifloxacin. Rates of resistance have increased significantly for all fluoroquinolones except sitafloxacin (Figure 1 ).
Resistance to fluoroquinolones differed for various Bacteroides species, with B. fragilis being the most susceptible and B. vulgatus the most resistant (Figure 2 ). During the study period, a large increase in fluoroquinolone resistance was observed for all Bacteroides species, with B. fragilis remaining the most susceptible and B. vulgatus the most resistant (Figure 3) . The largest increase in trovafloxacin resistance (MIC breakpoint of 8 mg/L) was among B. vulgatus, from 7% in 1994 to 55% in 2001. The largest increase in moxifloxacin resistance (MIC breakpoint of 4 mg/L) was among B. distasonis, from 22% in 1999 to 37% in 2001 (Figure 3 ).
An increase in the rates of fluoroquinolone resistance was observed among isolates recovered from all sites of infection ( Figure 4) . Isolates from decubitus ulcers were associated with the highest resistance rates to all fluoroquinolones tested (data not shown). Resistance to trovafloxacin among blood isolates increased from 6% in 1994-5 to 25% in 2000-1. Resistance to moxifloxacin among blood isolates increased from 38% in 1998 to 52% in 2001 (Figure 4 ).
An increase in fluoroquinolone resistance was observed for all but one of the hospitals that participated in this survey (data not shown). Whereas only small variations in trovafloxacin resistance were observed between hospitals in 1994 (range of 4-11%), large variations were observed in 2001 (range of 15-38%). For moxifloxacin, variations in resistance rates between hospitals were already high in 1998 and remained so in 2001 (22-49%).
High levels of cross-resistance were found between fluoroquinolones. Only 0%, 0.1% and 0.3% of isolates that were resistant to sitafloxacin, clinafloxacin and trovafloxacin, respectively, were susceptible to moxifloxacin. Only 1.7% and 2.5% of isolates that were resistant to clinafloxacin and sitafloxacin, respectively, were susceptible to trovafloxacin.
In multivariate analysis, the association between year of isolation and increased rate of resistance to trovafloxacin and moxifloxacin remained statistically significant after adjustment for hospital, Bacteroides species, and site of isolation. Adjusted odds ratios were 1.31 for trovafloxacin and 1.33 for moxifloxacin (P < 0.001).
Discussion
In contrast to findings from current and previous studies, we describe the emergence of high-prevalence fluoroquinolone resistance among Bacteroides species isolated in the United States. The significant increase in MICs of trovafloxacin, moxifloxacin and clinafloxacin observed during the study period is associated with increased rates of resistance to trovafloxacin and moxifloxacin at each of the MIC breakpoints analysed. This increase in resistance was observed among all Bacteroides species, all sites of isolation, and all but one of the participating hospitals. The increase in resistance could not be explained by changes in hospital participation, sites of isolation, or distribution of Bacteroides species, that might have occurred during the study period. A change in the in vitro medium used for testing occurred after 1996 and could potentially affect our results. However, this change was only applicable for trovafloxacin and trends of susceptibility to this medication after 1996 were similar to the overall trends, for all drugs tested since 1997, including trovafloxacin, suggesting that the change in medium had no significant effect on the conclusions drawn from this study. Moreover, we and others previously demonstrated that brain-heart infusion, used by us before 1997, and Brucella agar, used since 1997, are highly correlated with respect to the results of susceptibility testing. 27, 28 The large increase in fluoroquinolone resistance among blood isolates is of particular concern. Over 50% of 2001 blood isolates were resistant to moxifloxacin when an MIC breakpoint of 4 mg/L was used. This high-level resistance raises concern about the use of moxifloxacin for the empiric treatment of Bacteroides bacteraemia. Since the level of in vitro activity of other antimicrobials against Bacteroides has been shown to be predictive of treatment success, there is concern that the resistance noted in this study may result in treatment failure. 29, 30 We observed large differences in fluoroquinolone resistance across different Bacteroides species and sites of isolation. Rates of resistance to trovafloxacin in our cohort ranged from 4% for B. fragilis isolated from the female genital tract to 36% for B. vulgatus isolated from skin and soft tissues. Moxifloxacin resistance rates ranged from 17% for B. fragilis isolated from the female genital tract to 71% for B. vulgatus isolated from skin and soft tissues. Resistance patterns observed among different species and sites of isolation were consistent across different hospitals.
The large differences in fluoroquinolone resistance observed among the participating hospitals might be the result of differences in patterns of fluoroquinolone use in these hospitals and related communities. High rates of resistance observed in soft tissue isolates, particularly decubitus ulcers, may be explained by the fact that patients with such infections tend to be exposed to multiple antibiotics for long periods of times. Since most microbiology laboratories do not routinely provide antibiotic susceptibilities for Bacteroides isolates, therapy of these infections remains empiric. Any data that can lead to better choice of empiric antibiotics might potentially increase treatment effectiveness. The large variability in resistance observed in our study suggests that knowledge regarding species and site of isolation can be used to guide choice of antibiotics.
Of particular interest are the high rates of resistance to trovafloxacin and moxifloxacin observed among Bacteroides isolates isolated before the introduction of these medications into clinical practice. Although trovafloxacin was introduced into clinical practice only during 1998, a steady increase in MIC and resistance was already observed from 1994 to 1997, suggesting that selection of resistance due to cross-resistance with older fluoroquinolones such as ofloxacin or ciprofloxacin might have occurred. Even more interesting is the steady increase in moxifloxacin MICs before its introduction in December of 1999. As compared with older fluoroquinolones, resistance to the newer quinolones is expected to emerge at a slower rate because two DNA gyrase mutations, rather than one as in older fluoroquinolones, are required to confer resistance. 21 The rapid emergence of moxifloxacin resistance among Bacteroides might suggest that the main mechanism of resistance in these bacteria is other than mutations in bacterial DNA gyrase, perhaps involving an efflux pump. Such a mechanism was recently described in Bacteroides but its clinical importance is still unclear. 31, 32 The generalizability of our findings and their relationship to other data generated worldwide need further exploration. Our results might overestimate rates of resistance because of the selected participation of large tertiary care US medical centres in this study. As compared with small non-teaching hospitals, large centres tend to report higher rates of antibiotic resistance. In addition, quinolone use in some other countries is not as prevalent as it is the USA. However, since the use of quinolones in small hospitals and in the community has markedly increased during recent years, trends in resistance reported in this study are likely to reflect trends in these settings. The reported trends might help predict emergence of fluoroquinolone resistance in countries where quinolone use is not as prevalent as it is in the USA once it manifests itself.
The risk factors and reasons for fluoroquinolone resistance in Bacteroides remain to be explained. However, regardless of the cause, which may be the extraordinary increase in usage of quinolones for the treatment of respiratory tract infections, the implications of these findings indicate that fluoroquinolone resistance in Bacteroides may preclude its utility for serious anaerobic infections. 
